Evotec AG (NASDAQ:EVO) Short Interest Update

Evotec AG (NASDAQ:EVO) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 409,474 shares, a growth of 17.2% from the March 31st total of 349,478 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 89,057 shares, the days-to-cover ratio is currently 4.6 days.

Evotec Trading Down 0.6%

NASDAQ EVO traded down $0.02 on Friday, reaching $3.09. The company had a trading volume of 12,968 shares, compared to its average volume of 121,014. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.07 and a quick ratio of 1.99. Evotec has a 1-year low of $2.31 and a 1-year high of $4.80. The company’s fifty day moving average is $2.86 and its 200-day moving average is $3.24.

Evotec (NASDAQ:EVO) last announced its earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $297.02 million during the quarter. Evotec had a negative net margin of 13.13% and a negative return on equity of 12.40%. Research analysts forecast that Evotec will post -0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EVO. Bank of America Corp DE grew its holdings in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Evotec during the second quarter worth about $66,000. Marshall Wace LLP bought a new position in shares of Evotec during the second quarter worth about $169,000. BNP Paribas Financial Markets grew its holdings in shares of Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after buying an additional 4,600 shares in the last quarter. Finally, Snowden Capital Advisors LLC bought a new position in shares of Evotec during the second quarter worth about $122,000. 5.81% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on EVO shares. HC Wainwright started coverage on Evotec in a report on Wednesday, April 15th. They issued a “buy” rating and a $7.00 price target for the company. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Berenberg Bank started coverage on Evotec in a report on Tuesday, February 3rd. They issued a “buy” rating for the company. Finally, Weiss Ratings upgraded Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Evotec presently has an average rating of “Moderate Buy” and an average target price of $7.00.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.